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Diabetic macular edema (DME), a serious eye complication caused primarily by hyperglycemia, is one of the major
causes of blindness. DME, which is characterized by cystic retinal thickening or lipid deposition, is prone to relapse
after successful treatment. DME is a complex pathological process caused by multiple factors, including breakdown
of the inner and outer blood-retinal barriers, oxidative stress, and elevated levels of vascular endothelial growth
factor which have been demonstrated in both preclinical and clinical studies. Starling’s law theory explains many of
the features of DME. Early detection and treatment of DME can prevent vision loss. Current effective interventions
for DME include treatment of systemic risk factors, such as elevated blood glucose, blood pressure and dyslipidemia.
Ophthalmic treatments include laser photocoagulation, surgery and intraocular pharmacotherapy. New drugs, which
are given by intraocular injection, have emerged in recent years to become first line treatment for DME that affects
the central macula with loss of vision. Laser photocoagulation is still the gold standard of treatment for DME which
does not involve the central macular. This review outlines these new treatments with particular emphasis on the
optimal timing of how they are given.
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Diabetic retinopathy (DR) and diabetic macular edema
(DME), serious eye conditions caused primarily by
hyperglycemia, are the major cause of loss of vision and
blindness in the working population of developed coun-
tries [1]. The pathogenesis of DME has not been fully
elucidated since it is caused by complex pathological
process with many contributing factors. Dysfunction of
the inner and outer retinal barriers leads to accumula-
tion of sub- and intra-retinal fluid in the inner- and
outer-plexiform layers. Vascular endothelial growth fac-
tor (VEGF) has generally been accepted as the main
factor that disrupts the inner blood-retinal barrier (BRB)
function, making it an important target for pharmaceu-
tical intervention [2].* Correspondence: zhangxy1@trhos.com; wningli@163.com
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unless otherwise stated.Breakdown of the outer, especially the inner retinal
blood barrier is an early event in the pathogenesis of DME
[2]. Hypoxia, ischemia, oxygen-free radicals and inflam-
matory mediators are all involved in the breakdown retinal
blood barrier (BRB). Muller cell, pericyte and glial cell dys-
function combined with vitreous changes are involved in
the occurrence and development of macular edema.
Chronic hyperglycemia, hypertension and high cholesterol
are also important factors related to the incidence of
macular edema [3].
A large body of clinical data has confirmed that early
detection and treatment of DME is an effective strategy
to prevent vision loss [4]. Effective systemic interven-
tions for DME include control of blood glucose, blood
pressure and dyslipidemia. Ophthalmic treatments are
laser photocoagulation, surgery and intraocular phar-
macotherapy. Laser photocoagulation is still the gold
standard for DME which central macular is not involved.
This review outlines new treatment strategies, with par-
ticular emphasis on the optimal window for a variety of
therapeutic DME interventions.Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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DME is the major cause of vision loss associated with
DR. There are approximately 93 million people with DR,
17 million with proliferative DR, 21 million with DME
and 28 million with VTDR, the overall prevalence of
DME is 6.81% (6.74–6.89) for DME in people with dia-
betes worldwide [5], accounting for 12% of new cases of
blindness annually [6]. According to studies of the na-
tural history of DME, 24% of eyes with DME will lose at
least three lines of vision within3 years [7].
The prevalence of DME depends on the type and dura-
tion of diabetes. In patients with type I diabetes, DME oc-
curred in the first 5 years following diagnosis of diabetes,
with the prevalence gradually increasing to 40% over
30 years. The Diabetes Control and Complications Trial
(DCCT) group reported that the incidence of DME in type
I diabetes patients with a 9-year diabetic history was 27%
[8]. Around 5% of type II diabetes patients had DME when
diabetes was diagnosed, gradually increasing to 30% within
25–30 years. A Chinese population-based epidemiological
study reported that the prevalence of DME in type II
diabetes was 5.89% [9], while it was 4.3% in Beijing metro-
politan areas [10] and 5.2% in rural areas [11].
Several systemic risk factors have been identified in popu-
lation-based epidemiological studies. In patients <30 years
old, independent risk factors for DME included duration
of diabetes, proteinuria, gender, history of cardiovas-
cular disease, use diuretics and elevated HbA1C. In pa-
tients >30 years old, the incidence of DME is associated
with longer duration of diabetes, elevated systolic blood
pressure and elevated glycosylated hemoglobin. Pro-
teinuria was positively associated in insulin-dependent pa-
tients but not in the group that were not using insulin.
The prevalence of DME was also significantly associated
with high serum cholesterol levels in patients with type I
diabetes [12]. A sharp reduction (from 2.3% and 0.9%) in
the prevalence of DME was noted in a Wisconsin popula-
tion with better blood glucose control over two decades,
confirming that chronic hyperglycemia is a critical factor
in the pathogenesis of DME [13]. According to the new
meta analysis data in 2013, All DR prevalence end points
increased with diabetes duration, hemoglobin A1c, and
blood pressure levels and were higher in people with type
1 compared with type 2 diabetes [5].The pathogenesis of diabetic macular edema
Chronically elevated blood glucose, high cholesterol, the
accumulation of oxygen free radicals and of advanced gly-
cation end products (AGE)/AGE receptors, protein kinase
C (PKC) and other factors have all been implicated in the
pathogenesis of DME [3]. These factors ultimately con-
tribute to an increase in VEGF-A expression, resulting in
breakdown of the BRB.Mechanisms of diabetic blood-retinal barrier breakdown
The blood-retinal barrier (BRB)
The concept of the BRB, originating from the discovery of
the blood–brain barrier, was first introduced by Ashton in
1965 based on the study of histamine-induced leakage
from the ocular vessels [14]. In this study, significant vas-
cular leakage was observed in many compartments of the
eye, but retinal vessels were not affected. Shakib and
Cunha-Vaz then confirmed the presence of “zonulae
occludins” (tight junctions), epithelial cell-like structures
between the endothelial cells of the retinal vessels, using
electron microscopy [15,16]. The BRB is formed by exten-
sive junctional complexes found between retinal pigment
epithelial (RPE) and vascular endothelial cells. These com-
plexes selectively prevent molecules from passing into the
extracellular tissue of the retina [17]. The breakdown of
BRB results in accumulation of plasma proteins (e.g. albu-
min) which exert a high oncotic pressure in the neural
interstitum, which tends to produce interstitial edema.
Tight junctions
Tight junction-associated proteins play a critical role in
maintaining the normal biological function of the retina.
The tight junctions of the BRB constitute a biological and
mechanical barrier to solute flux between cells (para-
cellular permeability), allowing the organism to control
transport of nutrients and waste products through the cell
(trans-cellular permeability) [18]. Several reviews have
outlined the molecular functions of tight junction proteins
[17], the signaling cascade from and to the tight junction
complex [19] and the modulation of tight junction func-
tion in retinal vascular diseases, especially in in vitro stu-
dies DR [20,21].
Three integral proteins form tight junction complexes:
occludin, claudins and junctional adhesion molecules
(JAMs). Occludin and claudins are trans-membrane pro-
teins, predicted to have four trans-membrane and two
extra-cellular domains, which are the major structural
components of tight junction strands [17]. Occludin, first
discovered as a 65 kDa protein in chicken, has been shown
to play an important role in regulating tight junction bar-
rier function [22]. Claudins are a group of proteins that
includes 27 members [23]. JAMs belong to the immuno-
globulin super-family and are located close to tight junc-
tion strands [17,24]. There are also a group of proteins
named membrane-associated guanylate kinase homologs
(MAGUKs) that are positioned on the cytoplasmic surface
of junctional contacts. Zonula occludens (ZO-1) belongs
to the MAGUKs family and is thought to interact with
occludin [25] (Figure 1).
The functions of tight junction-associated proteins have
been investigated in vitro. Increased expression of occlu-
din has been shown to correlate with improved BRB func-
tion [26]. Functions of claudins may include maintaining
Figure 1 The inner blood retinal barrier and tight junction
proteins. Three integral proteins form tight junction complexes:
occludin, claudins and junctional adhesion molecules (JAMs) &
endothelial cell-selective adhesion molecule (ESAM). Tricellulin is a
recently discovered tightjunction protein that contributes to the
structure and function of tricellular contacts of neighboring cells in
many epithelial tissues Occludin and claudins are trans-membrane
proteins, predicted to have four trans-membrane and two extra-cellular
domains, which are the major structural components of tight
junction strands. There are also a group of proteins named
membrane-associated guanylate kinase homologs that are
positioned on the cytoplasmic surface of junctional contacts.
Zonula occludens (ZO) belongs to the MAGUKs family and is
thought to interact with occlude.
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flux through their key selectivity role in the para-cellu-
lar conductance of ions (such as Na+ or Cl−) [27,28].
JAMs are thought to interact with other tight junction-
associated proteins to regulate barrier function [29].
JAMs have additionally been demonstrated to interact
with leukocytes and be involved in mediating inflamma-
tory responses [30,31].
The correlation between tight junction-associated pro-
teins and diabetes-induced breakdown of the BRB has
been investigated in several studies. Elevated expression of
VEGF-A correlates with increased vascular permeability,
concomitant with decreased ZO-1 content in the vitreous
of patients with DR [32]. Diabetes also selectively reduces
the expression of occludin in the diabetic rat retina in
parallel with increased BRB permeability. The consequent
increased expression of VEGF-A has also been demon-
strated to lead to a rapid phosphorylation of occludin and
ZO-1, both in vivo and in vitro [33]. Expression of ZO-1
and occludin at the cell border is correlated with im-
proved BRB function in vitro [34].
In summary, tight junction-associated proteins are key
dynamic regulators of the BRB. Dysfunction of these
proteins is highly correlated with the pathogenesis of
BRB breakdown.VEGF-A, a major regulator of blood retinal barrier
breakdown in diabetic retinopathy
Introduction
VEGF (also referred to as VEGF-A) was first identified as
a 34–42 kDa protein in 1983 [35] and cloned in 1989 [36].
On the basis of its ability to induce vascular leakage, mea-
sured by125I-labeled human serum albumin extravasation,
VEGF-A was originally recognized as a ‘vascular perme-
ability factor’ in guinea pigs [35]. On a molar basis, the
effect of VEGF-A on vascular permeability is estimated to
be 50,000 greater than that of histamine as evaluated by
the Miles vessel permeability assay [37].
Members of the VEGF family
VEGF-A belongs to the VEGF family that includes
placenta growth factor, VEGF-B, VEGF-C, VEGF-D and
VEGF-E. Among these VEGF members, VEGF-A has
been studied most intensively so far [38,39].
Human VEGF-A comprises at least five different iso-
forms: VEGF110, VEGF121, VEGF165, VEGF189 and
VEGF206.An alternative distal splice acceptor site in exon
8, named VEGF165b, which is an inhibitory splice variant
of VEGF-A was identified by Bates et al. [40]. The expres-
sion of VEGF165b was further evaluated in normal and dia-
betic human eyes, including the lens, sclera, retina, iris
and vitreous. VEGF165b was detected predominantly in
normal but not in diabetic vitreous. About 65% of total
VEGF-A in normal vitreous is VEGF165b, confirming that
VEGF165b is regarded as the endogenous inhibitor of
VEGFA [41].
VEGF receptors
Three tyrosine kinase receptors have been identified with
functionality that corresponds to the VEGF family members.
VEGF-A receptor-1 (fms-like tyrosine kinase-1, FLT-1) and
VEGF-A receptor −2 (fetal liver kinase-1, FLK-1) are acti-
vated by VEGF-A. FLK-1 has been also recognized as a
vascular permeability factor, since one of the critical
functions of FLK-1 is to regulate vessel permeability [42].
FLT-1 has been reported to be a negative regulator and a
‘decoy’ receptor of FLK-1 by several studies [2,43]. The
third receptor, VEGF receptor-3 (fms-like tyrosine kinase-
4, FLT-4) is thought to bind to VEGF-C and VEGF-D
[44]. Additionally, two co-receptors for VEGF-A, neuropi-
lin-1 (for VEGF165) and −2 (for VEGF145 and 165) have
also been identified as the isoform-specific receptors in
embryonic vessel formation [45].
Role of VEGF-A and its receptors in the pathogenesis of DR
and the breakdown of the BRB
It has been well accepted that FLK-1 is the principle me-
diator of VEGF-A’s effect on vascular permeability and
angiogenesis [46]. VEGF-A and FLK-1 have been studied
as vascular permeability inducers in different ischemic
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receptor, FLT-1, is still controversial.
Several hypotheses have been proposed to account for
the mechanism by which VEGF-A and its receptors con-
tribute to BRB dysfunction and development of DR,
which has also been extensively reviewed [47] and thus
will not be the focus of this review.
Leukostasis and inflammatory cytokines
Leukostasis, the accumulation of leukocytes on the lu-
minal surface of the retinal capillaries, is thought to be a
major contributor and early event in BRB dysfunction
[48]. Leukocyte adhesion causes endothelial dysfunction
and capillary non-perfusion in several ways.
Firstly, it has been demonstrated that leukostasis con-
tributes to DR through the up-regulation of intracellular
adhesion molecule (ICAM)-1, a critical molecular player
in leukostasis which mediates the adhesion of monocytes
and neutrophils to vascular endothelium. ICAM-1 has
been found to mediate retinal leukostasis, vascular perme-
ability and BRB breakdown in diabetes. The expression
ofICAM-1 is also significantly elevated in STZ-induced
diabetic retinas [49] as well as in human diabetic retinas
[50]. Furthermore, intravitreal treatment with gluco-
corticoids has been found to significantly attenuate the in-
flammatory responses concomitant with improved BRB
function through the inhibition of ICAM-1 expression in
STZ-rat retinas [51].
Secondly, BRB breakdown resulting from leukostasis
may be due to its interaction with VEGF-A. VEGF-A has
been shown to up-regulate the expression of adhesive
molecules in vitro, promoting inflammatory cell adhesion
to endothelium [52]. In vivo, increased expression of neu-
trophil CD11a, b, and 18, together with endothelial nitric
oxide synthase (eNOS), was induced by VEGF-A in dia-
betic rat retinas [53]. It has also been shown that the
principle pro-inflammatory cytokine, TNF is a mediator of
VEGF-A induced BRB breakdown in vitro [54]. Elevated
expression of ICAM-1 stimulated by VEGF-A was found
to be attenuated by pigment epithelium-derived factor
(PEDF) in a dose-dependent manner in STZ-diabetic rat
retinas [55]. Furthermore, inflammation and BRB dys-
function have been demonstrated to be abrogated by anti-
VEGF165 (164) aptamer (EYE001) treatment of diabetic
retinas, suggesting that the effect of VEGF-A on leukosta-
sis is highly correlated with the pathogenesis of DR [56].
Thirdly, leukostasis has been found to correlate with
inter-endothelial tight junction complex dysfunction and
disorganization. Leukostasis was found to induce ele-
vated expression of β-catenin and plakoglobin as well as
the disorganization of the vascular endothelial-cadherin/
catenin complex, all of which were abrogated by a leu-
kostasis inhibitor (an anti-integrin β monoclonal anti-
body) in vivo [57].Finally, leukocytes produce reactive oxygen species
(ROS) and inflammatory cytokines following binding to
the vascular endothelium, leading to increased vascular
permeability [58]. There is evidence that the BRB can be
preserved by non-steroidal anti-inflammatory drugs (as-
pirin, etanercept and meloxicam) by preventing retinal
vascular leakage through the suppression of TNF [59].
The significance of leukostasis in the pathogenesis of DR
provides new insights for the treatment of DR.
Animal experiments confirmed that serum elevated glu-
cose can promote (interleukin-6, IL-6), tumor necrosis fac-
tor (TNF), Lymphotoxin and cyclooxygenase-2 (COX-2)
expression [8]. The upstream inflammatory cytokines of
VEGF-A induce VEGF-A activation, which in turn leads to
the destruction of the BRB. It has been found that IL-6,
monocyte chemotactic protein-1 (MCP-1), and PEDF ex-
pression was significantly increased in the vitreous [17].
Nitric oxide (NO)
In the late 1980s, Furochgott and Zawadzki (1980) found
that vascular endothelial cells produce a substance which
may induce vascular smooth muscle relaxation. In 1987, it
was confirmed, and named the CM 17 endothelial cell-
derived relaxing factor (EDRF) [18]. Subsequently, it was
discovered that eNOS is closely related to metabolic ab-
normalities and cardiovascular diseases and is an im-
portant neurotransmitter involved in a variety of cellular
responses. eNOS is highly correlated with the retention of
leukocytes in the microcirculation and destruction of the
BRB [19]. Awata et al. also showed that polymorphisms of
the eNOS gene are one of the most important factors in
the pathogenesis of DME. eNOS gene polymorphisms not
only play an important role in the occurrence and deve-
lopment of the DME [20], but are also highly correlated
with the breakdown of the BRB. BRB breakdown is also
accompanied by the up-regulation of ICAM-1 and de-
creased expression of tight cell junction protein ZO-1. In
diabetic animals, vascular leakage was significantly re-
duced and the BRB was protected by the NOS inhibitor
L-NAME [21], verifying the biological roles for eNOS in
the pathogenesis of DME, including: (1) induction and re-
tention of inflammatory cells in the microcirculation of
the eye; (2) a direct effect on cell junction proteins, de-
creasing the expression of cell junction proteins; and (3)
increasing the expression of VEGF-A which leads to the
destruction of the BRB.
Retinal neurovascular unit
The nervous and the vascular systems are two parallel
systems during embryonic development. They mutually
support each other to achieve the promotion of the for-
mation of blood vessels and nerves occur. In relating the
physiological functions, retinal neurons rely on their
close link to ensure the supply of oxygen and nutrients
Zhang et al. Cell & Bioscience 2014, 4:27 Page 5 of 14
http://www.cellandbioscience.com/content/4/1/27from the micro-vascular; vasodilation of the blood vessels
rely on physiological activities of the nerves; anatomically,
retinal neurons, pericytes, mullers, micro-vascular as well
as astrocytes are close located. In our previous study, it
has been found that neuronal apoptosis and micro-
vascular leakage are mutual coexist and interactions. In
addition, our study also revealed that VEGFA is a micro-
vascular leakage and neuronal apoptosis inducer, both
micro-vascular and neurons are effected by VEGFA. The
concept of neurovascular unit which contains the brain
blood retinal barrier, pericyte, atrocyte, neurons, was ori-
ginally from the study of stroke, the retina is an extension
of the brain and is a part in the visual pathway; fur-
thermore, there are many similarities between the micro-
structure of brain and retina, such as existing of the
blood-retinal barrier, glial cells, pericytes surrounding neu-
rons, and other anatomical structures, based on the above
points, we proposed a concept of “retinal neurovascular
unit” as long with Antonitte’s group [60] (Figure 2).
Among the retinal neurovascular unit, Muller cells (glial
cells) are located between the retinal neurons, functioning
as an exchange bridge in the microcirculation and bet-
ween neuronal cells. Muller cells are also considered to be
an important component of the BRB, as anatomically,
Muller cell synapses surround the inner retinal blood ves-
sel walls. Cytoplasmic swelling of Muller cells is an early
histopathological change in macular edema, resulting in
the intracellular accumulation of extracellular fluid. It has
been found that the expression of cell junction proteinFigure 2 Retinal neurovascular unit. The retinal neurovascular
unit contains the retinal blood retinal barrier, pericyte, glial cells
(astrocytes and Muller cells), neurons.ZO-1 is increased, the normal BRB function is maintained
by Muller cells. ZO-1 and occludin have been recognized
as important tight junction proteins; the interactions bet-
ween ZO-1, occludin, as well as perivascular Mullers, glial
cells and pericytes play a very important role in main-
taining the normal function of the BRB [22]. In addition,
under pathological conditions, several growth factors
are secreted from the perivascular astrocytes including
basic fibroblast growth factor (bFGF), interleukin-1 (IL-1),
transforming growth factor-β (TGF-β), vascular endothe-
lial growth factor (VEGF), r-interferon (IFN-r), TNF and
insulin-like growth factor (IGF-1), resulting in the break-
down of the BRB [23-26].
Protein kinase C
More details can be found in Section "Hyperglycemia
and its metabolic pathways 1".
Hyperglycemia and its metabolic pathways
Whilst the etiology of DR is highly complex and not
fully understood, hyperglycemia has been accepted as
the major pathological factor contributing to the deve-
lopment of DR. Four distinct glucose metabolic path-
ways are activated by hyperglycemia (Figure 3):
1 Diacylglycerol (DAG)–protein kinase C (PKC)
pathway. Hyperglycemia increases synthesis of DAG
via the de novo pathway, which in turn activates
PKC isoforms reviewed [61]. The pathogenic role of
the DAG-PKC pathway in the pathogenesis of DR
has been demonstrated in both human and animal
studies [62,63].
PKC, one of a family of serine/threonine protein
kinases of which there are at least 12 known
isoforms, has been implicated in the pathogenesis of
diabetic BRB breakdown both in vivo and in vitro
through a variety of mechanisms [64]. Firstly, its
effect is mediated via VEGF-A [65]. The regulation
of VEGF-A gene expression has been shown to be
controlled and enhanced by PKC-β in a transgenic
mouse model [66]. The mitogenic effects of VEGF-A
are also mediated by the activation of PKC-β
in vitro. Secondly, PKC can be activated by oxidative
stress through ROS produced by hyperglycemia or
advanced glycation end-products (AGEs), shown to
directly activate PKC [67]. Thirdly, PKC triggers
phosphorylation of tight junction-associated proteins
to induce BRB breakdown. Phosphorylation of
occludin and ZO-1 was shown to correlate with the
activation of PKC in diabetic BRB dysfunction in
STZ rats [68]. On the other hand, increased vascular
permeability was shown to be suppressed by a
PKC-β selective inhibitor, ruboxistaurin mesylate
(LY333531) in diabetic rat retinas [69]. The oral
Figure 3 Hyperglycemia and its metabolic pathways. Four distinct glucose metabolic pathways are activated by hyperglycemia: Diacylglycerol
(DAG)–protein kinase C (PKC), advanced glycation endproducts/ receptor for advanced glycation end-products, Polyol (sorbitol) and Hexosamine
pathways. Activation of the metabolic pathways leads microvascular dysfunction, neuronal apoptosis, glial reactivity and component deposition.
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clinical trials of DR. An initial report from this phase
III clinical trial suggested that administration of
32 mg LY333531 per day may reduce vision loss in
patients with DME, however, this trial did not meet
its primary endpoint (The PKC-DRS Study Group,
2005). Another phase III randomized clinical trial on
the effect of ruboxistaurin on progression of DME is
underway.
PKC is also involved in hyperglycemia-induced
retinal neuronal apoptosis. This may be mediated
through inhibition of Akt-mediated signaling
pathways modulated by the activation of PKC-δ
in vivo [70]. Phosphorylation/activation of the
apoptotic regulator p38MAPK in response to
hyperglycemia stimuli was also found to be mediated
through activation of PKC [71].
2 Advanced glycation end-products. Intracellular
elevated glucose reacts non-enzymatically with the
amino group of proteins, lipids and nucleic acids to
form a reversible Schiff base, which is subsequently
converted to the stable Amadori product (glycation
product) and further metabolized to AGEs [72].
AGEs modulate cellular function mediated through
binding of their specific acceptor molecules.
Receptor for AGE (RAGE) was identified and
characterized as a 35 kDa, lactoferrin-like AGE
binding receptor expressed on endothelial cells [1].
Binding of AGEs by RAGE leads to endothelial
dysfunction and BRB breakdown in DR. In a RAGEtransgenic mouse model, AGEs/RAGE interaction
was shown to induce leukostasis and BRB
breakdown, which was attenuated by a soluble form
of RAGE [73]. Dysfunction of endothelial progenitor
cells was found to be induced by AGEs/RAGE
through the p38MAPK pathway [74]. AGEs/RAGE
interaction is also believed to trigger oxidative stress
[75], the release of pro-inflammatory cytokines [76]
and increased expression of VEGF-A [77], leading to
further diabetic BRB breakdown and neuronal
degeneration in the retina.
AGEs are neurotoxic to retinal neurons. In vitro,
retinal neuronal cell death induced by AGEs and
hyperglycemia has been shown to occur in a
time- and dose-dependent manner and be mediated
through the activation of ROS, suggesting oxidative
stress is a consequence of AGEs/RAGE interaction
[78]. Both AGEs and ROS have been demonstrated
to induce retinal ganglion cell degeneration, possibly
mediated by PI3 kinase-dependent pathways [75].
3 Polyol (sorbitol) pathway. Hyperglycemia leads to
elevated levels of intracellular glucose, which is then
converted to sorbitol by the enzyme aldose
reductase using nicotinamide adenine
dinucleotideüü phosphate as a cofactor. Sorbitol is
subsequently metabolized to fructose, a step which
is rate-limiting.
Activation of the sorbitol pathway leads to DR.
Activation of the enzyme aldose reductase and
accumulation of sorbitol was found in retinal
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retinas [79,80]. Excess accumulation of sorbitol and
fructose have been demonstrated to correlate
strongly with diabetic micro-vascular dysfunction
[81], neuronal apoptosis [82], glial reactivity and
complement deposition [83]. The selective aldose
reductase inhibitors fidarestat and aldose reductase
inhibitor-809, have been demonstrated to
significantly abrogate neuronal apoptosis by
inhibition of oxidative-nitrosative stress and
glial cell activation in STZ-induced diabetic rat
retinas [83,84].
4 Hexosamine pathway. Hyperglycemia induces
mitochondrial superoxide over-expression, and leads
to the activation of the hexosamine pathway [67].
Activation of this pathway has been found to
induce oxidative stress [85], production of some
pro-inflammatory cytokines such as TGF-α [67], −β
[86] and plasminogen activator inhibitor [87], which
subsequently induce diabetic retinal neuronal
apoptosis [88], endothelial dysfunction [89] and BRB
breakdown [90].
In peripheral nerves, hyperglycemia is associated with
neuronal degeneration by directly reducing nerve endo-
neurial blood flow and causing nerve hypoxia which leads
to reduced nerve conduction velocities, axonal loss, de-
myelination and nerve dysfunction [91,92].
Hydrodynamic principles
The starling principle
Capillary fluid movement is composed of three pro-
cesses: diffusion, filtration and pinocytosis. Starling’s
equation reflects the mechanism of fluid filtration across
the vascular membranes. The Starling principle empha-
sizes the pressure difference between the hydrostatic and
osmotic forces of liquid flow as the driving force which
contributes to macular edema. The Starling equation is
as follows:
Jv ¼ Kf Pc−Pi½ −σ πc−πi½ ð Þ
Where Jv is the net fluid movement between compart-
ments, [Pc–Pi]–σ [πc–πi] is the net driving force, Pc is
the capillary hydrostatic pressure, Pi is the interstitial
hydrostatic pressure, πc is the capillary oncotic pressure,
πi is the interstitial oncotic pressure, Kf is the filtration
coefficient – a proportionality constant, and σ is the re-
flection coefficient.
Intravascular fluid penetrates into the tissue, results in
liquid accumulation in the outer plexiform layer of the
macular area caused by the high intravascular osmotic
pressure due to high blood glucose. Retinal arterioles also
contribute to increased vascular resistance and maintainthe downstream pressure balance, causing dilation of
small caliber arteries. According to the Starling principle,
along with the pressure decrease of the branch of the
ciliary vessels, the resistance decreases, the consequence
of which induces fluid retention between cells.
The Young-Laplace equation
The Young-Laplace equation, a nonlinear partial differen-
tial equation also describes the papillary pressure differ-
ence over an interface in fluid mechanics. The Young-
Laplace emphasizes aspect of static capillary surface and
elucidate the pressure difference is due to the shape of the








Under the condition that only normal stress( in the
absence of tangential stress) is considered, Δp is the
pressure difference across the fluid interface, y stands for
the wall tension, n^ is the unit normal pointing out of the
surface, H is the mean curvature, and R1 and R2 are the
principal radii of curvature.
Vitreous
Vitreous is located just behind the lens and in front of
the retina, acting as a buffer to resist external forces and
seismic effects. Containing viscoelastic resin, soluble
proteins, glucose, free amino acids, and electrolytes, vit-
reous is a major component of the refractive substance
in the eye. Due to the important anatomical correlation
with the retina, it also functionsin metabolism and trans-
portation – the macromolecules in the retinal vascular
are prevented from moving into the vitreous by the BRB,
while normal vitreous can inhibit the proliferation of a
variety of cells to maintain intravitreal environmental
stability. A large number of studies have confirmed that
the vitreous plays an important role in the pathogenesis
of DME. In Ouchietal’s study using two-dimensional gel
electrophoresis and mass spectrometry, eight proteins in
the DME group were significantly up-regulated, inclu-
ding six major cytokines of PEDF, Apolipoprotein A-IV
(APoA-4), ApoA-1, Trip-11, and plasma retinol-binding
protein, suggesting that these proteins are involved in
the pathogenesis of DME in patients with DR [93]. It
was also found that the expression of PEDF in DME
vitreous was significantly increased, suggesting that
vitreous inflammation plays an important role in the
pathogenesis of DME [50,93].
The interaction between the vitreous and retina has
been found to be involved in the development of macular
edema; in particular, when the vitreous and the macular
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can be greatly promoted [94]. Posterior vitreous detach-
ment occurs when the posterior cortex of the vitreous
separates from the internal limiting membrane for se-
veral reasons. It was found that the incidence of DME is
much lower in diabetic patients with PVD compared
with those subjects without PVD (20% versus 55%), sug-
gesting a strong protective effect of PVD [95] This con-
clusion has also been confirmed by Okulistycznego and
his colleagues [96].
In summary, the proposed mechanism of vitreous in the
pathogenesis of DME may be due to: (1). the mechanical
tractional effects of the epiretinal membrane (ERM). Break-
down of the BRB results in the accumulation of a large
number of inflammatory cytokines in the posterior vitreous
cortex and is highly correlated with ERM formation. Trac-
tional effects of the ERM in the tangential direction of the
macular area aggravates existing macular edema.(2) The
direct effects of cytokines due to the breakdown of the
blood-vitreous barrier. Breakdown of the vitreous-retinal
barrier is correlated and is the sequence of breakdown of
BRB. Accumulation of growth and inflammatory factors in
the macular posterior vitreous cortex contributes to the
formation of EPM, eventually aggravating macular edema.
Genetic factors
It is well accepted that susceptibility to DME is attrib-
uted to a combination of both genetic and environmen-
tal factors in individuals.
DR and DME are caused by complex genetic and envir-
onmental factors, varying between individuals. Homo-
zygosity of the methyl-enetetrahydrofolatereductase gene
(677 T/677 T) polymorphism was shown to correlate
highly with the progression of DR in patients with type II
diabetes, especially in those with poorly controlled serum
glucose [97]. Polymorphisms of eNOS [98], obesity-
related genes (db/db and ob/ob) [99], TGF-β1 and -β2
stimulated clone-22 genes [100], have also been proposed
to contribute to the development of D polymorphisms in
erythropoietin [34], eNOS [20] and VEGF-A genes, and
are considered important in the pathogenesis of DME. A
meta-analysis of population-based studies (973 patients,
1856 controls, SNP2543887) has shown that the rs476141
gene which is located in chromosome 1, is closely related
to the pathogenesis of proliferate DR and macular edema
(sight-threatening retinopathy) [35]. VEGF-B gene also
promotes BRB breakdown and the formation of retinal
neovascularization [36].
Diagnosis and classification of diabetic macular
edema
DME is clinically classified as diffuse, focal or both. DME
is characterized by microaneurysm formation and diffuse
leakage from the retinal capillaries or even arterioles[101]. Diffuse leakage may also come across the RPE due
to the dysfunction of RPE transport induced by degene-
ration of RPE cells and choroidal vascular insufficiency
[102]. In this type of DME, cystoid macular cavity for-
mation can be detected by OCT and/or FFA [103]. Focal
macular edema is characterized by the presence of micro-
aneurysms and hard exudates rings or ‘circinate exudates’,
surrounding the leaking microaneurysms [103].
Four categories of DME have been established based
on OCT: (1) diffuse DME (DRT) which is characterized
by retinal thickening, weakening of the light reflection
and irregular low reflex zone; (2) cystoid macular edema
(CME): a cystoid dark cavity can be visualized; (3) serous
sensory detachment DME (SRD) which is characterized
by neuronal sensory or even pigment epithelial detach-
ment which can be visualized by OCT; (4) vitreomacular
traction(VMIA): this type is characterized by incomplete
or complete posterior vitreous detachment, and ERM
formation or vitreomacular traction or both exists [37].
Clinically significant macular edema (CSME)
The Early Treatment Diabetic Retinopathy Study Group
defined the criteria for ‘clinically significant macular
edema’ as having any of the following characteristics [104]:
1. Thickening of the retina at or within 500 microns of
the center of the macula
2. Hard exudates at or within 500 microns of the
center of the macula, if associated with thickening of
adjacent retina (excluding residual hard exudates
remaining after disappearance of retinal thickening).
3. Retinal thickening at one disc area or larger, at any
part of which is within one disc diameter of the
center of the macula.
Treatment strategies for diabetic macular edema
Strict blood glucose, lipid and blood pressure control is
critical for prevention and treatment of DME. According
to the recommendations of the American Diabetes Asso-
ciation, HbA1C should be controlled at 6.5-7% and
blood pressure should be below 130/85 mmHg, with
total lipids lower than 100 mg/dL [39]. The purpose of
local eye treatment is to reduce swelling, control the
progression of the disease, and improve vision. Local
treatments for eyes with DME include laser photocoagu-
lation, vitrectomy surgery, and intravitreal injection of
drugs (glucocorticoid hormone, anti-VEGF agents and
PKC inhibitors) (Figure 4).
Traditional therapy
Laser photocoagulation remains the gold standard treat-
ment for DME. Focal macular laser treatment was demon-
strated to reduce the risk of moderate visual loss in eyes
with clinically significant DME from 28% to 11% at
Figure 4 Treatment strategies for diabetic macular edema. Strict blood glucose, lipid and blood pressure control is critical for prevention and
treatment of DME. According to the recommendations of the American Diabetes Association, HbA1C should be controlled at 6.5-7% and blood
pressure should be below 130/85 mmHg, with total lipids lower than 100 mg/dL. Local treatments for eyes with DME include laser
photocoagulation, vitrectomy surgery, and intravitreal injection of drugs (glucocorticoid hormone, anti-VEGF agents and PKC inhibitors).
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ized clinical trial in the USA [104]. The clinical outcomes
of scatter and focal laser treatment were compared in
diabetic patients with clinically significant DME. Com-
pared to scatter laser treatment, focal photocoagulation
was found to reduce moderate visual loss with no deleteri-
ous effects on visual fields over a 5-year follow-up [105].
Newly published data (2008) from the Diabetic Retinop-
athy Clinical Research Network demonstrated that over a
2-year follow-up period, focal/grid laser treatment was
more beneficial for visual acuity in patients with DME
compared to 1 or 4 mg intravitreal triamcinolone aceto-
nide (IVTA) treatment. In this multi-center clinical trial,
880 eyes of 693 patients with DME were enrolled; OCT
was used to monitor the retinal thickness, which was
found to parallel the visual acuity results. A significant re-
duction of retinal thickness from baseline to 2 years was
noted in the laser treatment group(139 ± 148 μm), com-
pared with 1 mg (86 ± 167 μm, p < 0.001) and 4 mg (77 ±
160 μm, p < 0.001) IVTA groups, suggesting that laser
still remains the benchmark treatment for patients with
DME [106]. Pan retinal photocoagulation (PRP) is an ef-
fective treatment for both high-risk non-proliferative
diabetic retinopathy (NPDR) and proliferative diabetic
retinopathy (PDR) to prevent or reverse pre-retinal neo-
vascularization. Focal or grid laser is applied for focal or
diffuse macular edema. It has been shown that the risk
of vision loss from advanced DR can be reduced by 50%
with PRP treatment [107].
Complications associated with photocoagulation in the
macula include choroidal neovascularization, hemorrhage,impairment of visual acuity, visual fields and contrast sen-
sitivity [108]. The mechanism of traditional photocoagu-
lation is to reduce the oxygen consumption by destroying
the outer segment of photoreceptors, and as a conse-
quence [109], the inner neuronal fiber layer may be da-
maged during the process of laser penetration. Many
efforts have been made to reduce the damage to the retina
by modifying the laser parameters, e.g. reduce the expo-
sure timing, use yellow beam, etc. A sub-threshold micro-
pulse laser has emerged in the clinic in recent years [110].
This works by reducing the duration of laser exposure
using a sub-visible clinical endpoint. The selective damage
to the RPE cells may lead to an improved balance in an-
giogenic factors and cytokine release [111]. The exposure
timing includes several on and off phases using a micro-
pulse mode, since the inner retinal temperature must re-
main sub-threshold to maintain its transparency [112].
Drugs
Anti-Vascular endothelial growth factor (VEGF) and its
receptor
In February 2004, Genentech VEGF inhibitor bevacizumab
(Avastin, 149 kDa) was fast-tracked for approval by the US
FDA. It was approved for joint 5FU-based regimens in the
first-line treatment of metastatic colorectal cancer and has
become the first approved drug listed for the inhibition of
tumor angiogenesis [41]. Another Genentech product,
Ranibizumab (Luncentis, 50 kDa), received FDA approval
in 2006 for the treatment of wet age-related macular
degeneration (wAMD). Anti-VEGF treatment has been
confirmed by many clinical trials for the treatment of a
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macular degeneration (AMD) [43], and macular edema
caused by central retinal vein occlusion [44]. Anti-VEGF
antibody is also combined with photodynamic therapy for
AMD [45]. However, all the clinical data available so far
have been derived from small-scale clinical trials, and fur-
ther validation for the treatment of vascular disease is
needed, including larger sample sizes or multi-center cli-
nical trials [41] (Table 1).
Pegaptanib sodium (Macugen; Eyetech, USA) was ap-
proved by the US FDA in December 2004 for the treat-
ment of wAMD. Pegaptanib is a synthetic anti-VEGF-A
aptamer (mw50kDa) and is highly selective for VEGF165
subtypes. In phase II and phase III clinical trials it was
shown that pegaptanib significantly inhibits new blood
vessel formation and improves visual function for pa-
tients with wAMD. In a multicenter, randomized, 1-year
clinical trial, 36.8% of the eyes with DME experienced
improvement of visual acuity to 10 letters (19.7% in the
control group) by intravitreal injection of 0.3 mg pegap-
tanib. This result suggests that pegaptanib is effective in
the treatment of DME [46].
In 2011, a new generation of anti-angiogenesis drug de-
veloped by the Regeneron biopharmaceutical company
(Regeneron Pharmaceuticals, Inc, NY USA) called afli-
bercept (VEGF-trap), was approved by the US FDA. VEGF
trap-eye is a fusion protein, with a molecular weight
of115kDa and has high affinity to specific receptor
VEGFR1 and VEGFR2 antagonists. Aflibercept has been
proven to inhibit a tumor’s progression effectively in the
VELOUR phase III clinical trial. Aflibercept combined
with 5-FU as the second-line regimen in the treatment of
metastatic colon cancer significantly prolonged the patient
survival. Intravitreal injection of aflibercept has been ap-
proved for the treatment of wAMD with visual acuity sig-
nificantly improved. Phase III clinical trials are currentlyTable 1 Current anti-VEGF agents on retinal diseases
Anti-VEGF agents Mode of action Mole
weig
Pegaptanib 28-base ribonucleic aptamer 50
Ranibizumab
(Lucentis, Genetech)
a monoclonal antibody fragment




Humanized anti-VEGF mAb, specific
against VEGF165. It was first used as





Recombinant VEGFR fusion protein that




A humanized fusion protein that binds
all forms of VEGFA,VEGF receptor 1
and 2 and the Fc portion of IgG1
143
AMD age related macular degeneration.
FDA food and drug administration.being validated for its efficacy in retinal vein occlusion-
induced macular edema and DME [47].
Glucocorticoid therapy
Systemic or ocular glucocorticoid treatment of eye dis-
eases, including DME has been in use clinically for more
than 50 years [48]. The anti-inflammatory [49] and di-
rectly anti-VEGF-A [1] effects for protection of the BRB
have been confirmed in animal and human studies. Tri-
amcinolone acetonide (TA) is a long-acting non-soluble
hormone used since the 1960s for the treatment of a
variety of eye inflammatory diseases [50,51]. Sub-Tenon’s
injection of TA was also used in the 1990s for the treat-
ment of macular edema secondary to various diseases
[52]. It has been shown that intravitreal injection of TA in-
hibits macular edema [48] and wAMD in a well-designed
clinical trial in 2003 [53]. In a 2-year, randomized clinical
trial, 56% of eyes had visual acuity improved by 5 lines in
the Snellen eye chart, corresponding to a decreased retinal
thickness using OCT [48]. It has also been found in se-
veral clinical trials that intravitreal injection, rather than
other delivery methods, is most effective, with the con-
centration in the vitreous cavity more than six times
higher than that with peribulbar administration (1.22 ±
0.24 mug/mL vs. 0.20 ± 0.11 mug/mL).
Three intravitreal TA injection doses of 1, 4 and 20 mg
have been used in clinical practice, with 4and 20 mg con-
sidered the most effective treatment doses [54,55]. Four
milligrams is the most widely accepted dose reported. In-
creased intraocular pressure and steroid-induced cataract
are the main complications of intravitreal injection with
TA. Gillies reported that after 2 years follow-up, a 4 mg
intravitreal administration was associated with increased
intraocular pressure in 44% of eyes, which required medi-
cation to control the intraocular pressure, while 55% of
eyes needed cataract surgery [48]. It was also reported thatcular
ht (kDa)
The phase III trail Year approved by FDA
Vision trial 2004 for wet AMD
Anchor, marina, pier
(wet AMD) Ride/rice(DME)
2006 approved by FDA for wet
AMD 2012approved by FDA for
diabetic macular edema
None for eye diseases 2004 approved by FDA for
colorectal cancer
VIEW 1 and VIEW2 for wet
AMD
2011 approved by FDA for wet
AMD 2012 European Medicines
Agency approved for AMD
Lamp, phoenix 2013 approved by cFDA for
wet AMD
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intraocular pressure was 41.2% (>21 mmHg), 11.4%
(30 mmHg), 5.5% (35 mmHg), and 1.8% (>40 mmHg).
Although the reported incidence of intraocular pressure
after IVTA treatment is different, only 1% of the eyes
needed trabecular filtration surgery to control the in-
creased intraocular pressure [56].
The lLUVIEN sustained-release fluocinolone acetonide
(FA) implant device - a new local via sub-Tenon’s or intra-
vitreal injection drug, has been shown to be effective in
the treatment of refractory DME and uveitis. In a 2-year
phase III clinical trial, 28.7% of eyes with DME had BCVA
improved to 15 letters on the ETDRS visual acuity chart.
The major adverse effect related to the implant, as de-
monstrated in clinical trials, is increased intraocular pres-
sure. Interestingly, it has been shown that intravitreal
administration of FA significantly protects retinal neurons
in the outer nuclear layer as evidenced by significantly
improve db-wave amplitude in electroretinogram (ERG),
suggesting its neuronal-protective effect [57].
OZUDEX is a dexamethasone sustained-release bio-
degradable drug. Intraocular OZUDEX has been shown
to be long-acting and effective for the treatment of per-
sistent refractory macular edema caused by branch and
central vein occlusion, DME, as well as non-infectious
uveitis in phase III clinical trials [58].
Protein kinase C inhibitor
The PKC inhibitor ruboxistaurin (LY333531) is a PKC-
beta specific inhibitor. LY33351 significantly inhibited
diabetic BRB breakdown and retinal neuropathy in a
pre-clinical animal study [60]. In a 3-year clinical trial to
test the efficacy and safety of ruboxistaurin, in 1392 eyes,
10.2% experienced moderate vision loss in the control
group; 6.1% experienced up to 15 letters in the study
group, 7.4% 11.7%. 26.7% respectively in the control
group and 35.6% of the eyes needs to be combined with
laser photocoagulation to prevent further loss of vision.
The results show that ruboxistaurin combined with laser
photocoagulation can effectively prevent the occurrence
of DME. However, the results need to be further vali-
dated by large-scale multi-center clinical trials.
Surgery - vitrectomy
Pars plana vitrectomy (PPV) surgery was introduced by
Machemer et al. in the early 1970s [113,114] and has been
widely used ever since. It has been confirmed by several
clinical trials that it effectively reduces macular edema, es-
pecially CME. The mechanisms by which PPV improves
macular edema include:(1) alleviation of the ischemic state
of the ischemic area of the retina, and prohibition of
the secretion of macromolecules for persistent macular
edema; and (2) an increase in the oxygen supply to the
retinal surface, enhancing absorption of oxidation of theretina thereby reducing macular edema. In addition, (3) vi-
trectomy could improve the water solubility of oxygen
and other nutrients in the vitreous cavity, thus facilitating
the transport of oxygen to the ischemic retinal areas [61].
The indications of PPV for PDR include: (1) PDR with
heavy and persistent vitreous hemorrhage; (2) PDR with
tractional retinal detachment; and (3) persistent DME
which cannot be improved by laser or anti-VEGF therapy
[115] (4) presence of vitreal-macular contraction and(5)
DME with heavy hard exudates [62].
The internal limiting membrane is a basement mem-
brane between the retina and vitreous, acting as the pro-
liferation of the bracket and participate in the formation
of macular degeneration. Dissection of the internal li-
miting membrane in macular hole surgery is a very im-
portant step in treating DME. The effectiveness of PPV
surgery for DME has been confirmed by several clinical
trials. A study of 26 DME patients who experienced vi-
trectomy surgery combined with ICGA-stained internal
limiting membrane dissection, indicates that vitrectomy
combined with internal limiting membrane peeling can
reach a better visual acuity prognosis for young diabetic
patients with recent vision loss due to macular edema
without laser photocoagulation [63]. Evidence from
some small-scale clinical trials also indicates that there is
no significant difference between the with-or-without
limiting membrane peeling groups in the prognosis of
visual function [64].
In summary, with the development of molecular biol-
ogy and basic science, there is now a more in-depth un-
derstanding of the pathogenesis of DME. Since BRB
breakdown has been recognized as the earliest mani-
festation of DME, prevention of BRB breakdown has be-
come the target of drug intervention and a hot topic for
research. A variety of anti-VEGF-A drugs have been
widely used clinically, and some new drugs are in devel-
opment or in phase I-III clinical trials. Achieving an in-
dividual therapy, according to the different complex
pathological conditions, has become the priority in the
development of an effective drug treatment strategy for
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